Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Cassava Science provided a business update. In November 2024, Cassava reported that the topline results from the Phase 3 RETHINK-ALZ study ...

NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn ...

Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $2.4 which represents a decrease of $-0.10 or -4.00% from the prior close of $2.5. The stock opened at $2.44 and touched a low of $2.

Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $2.36 which represents a decrease of $-0.04 or -1.67% from the prior close of $2.4. The stock opened at $2.36 and touched a low of $2 ...

Robbins LLP reminds investors that a class action was filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for wrongdoing between February 7, 2024 ...

Wellington Management Group LLP bought a new position in shares of Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report) during ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 ...

Robbins LLP reminds investors that a class action was filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for wrongdoing between February 7, 2024 ...